Somatrem

Somatrem

Somatrem

Pharmaceutical drug

Somatrem, sold under the brand name Protropin, is an analogue of growth hormone (GH).[1]

Quick Facts Clinical data, Trade names ...

Overview

Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone.

Somatrem was first marketed under the brand name Protropin by Genentech in 1985.[2] It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus[3][circular reference].

Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.

References

  1. [1]
    Flodh H (1987). "Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem)". Acta Paediatrica Scandinavica. Supplement. 331: 1–4. doi:10.1111/j.1651-2227.1987.tb17089.x. PMID 3300150. S2CID 20410776.
  2. [2]
    "Genentech: Press Releases - Friday, Oct 18, 1985". www.gene.com.
  3. [3]
    Growth hormone therapy#cite note-32
Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Somatrem, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.